Five Recent Deals Show ADCs Aren’t Cooling Off For Summer
Executive Summary
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.